NOVARTIS logo.jpg
Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day
June 18, 2015 01:00 ET | Novartis Pharma AG
Strong progress on innovation across divisions Pharmaceuticals is building breadth and depth in seven franchises, including Oncology, where it is complementing leadership in targeted therapies and...
NOVARTIS logo.jpg
Alcon receives European approval for new trifocal presbyopia-correcting intraocular lens for patients undergoing cataract surgery
June 16, 2015 01:15 ET | Novartis Pharma AG
Innovative AcrySof® IQ PanOptix®  trifocal intraocular lens design to improve near to intermediate vision and increase independence from glasses More than three million cataract surgeries...
NOVARTIS logo.jpg
Novartis presents new data from large European study reinforcing the benefit of first-line Tasigna® in newly-diagnosed patients with CML
June 13, 2015 09:45 ET | Novartis Pharma AG
Patients on Tasigna achieved rapid and high rates of molecular response with a very low rate of progression to advanced disease  ENEST1st data confirm the favorable benefit/risk profile of...
NOVARTIS logo.jpg
Novartis announces data show majority of patients with polycythemia vera treated with Jakavi® achieved long-term disease control
June 13, 2015 05:45 ET | Novartis Pharma AG
Preplanned analysis at 18 months demonstrate 80% of PV patients treated with Jakavi® (ruxolitinib) experienced a durable response for at least one year[1]  In the study, 83% of patients in the...
NOVARTIS logo.jpg
Novartis data at EHA show increased PFS benefit of Farydak® in new subgroup of patients with previously treated multiple myeloma
June 12, 2015 05:45 ET | Novartis Pharma AG
Panobinostat combination more than doubled median PFS benefit by 7.8 months in patients who received >=2 prior lines of therapy, including bortezomib and IMiD[1] Multiple myeloma is an...
NOVARTIS logo.jpg
Novartis drug Arzerra® improved median progression-free survival by 54% in patients with relapsed chronic lymphocytic leukemia
June 12, 2015 02:30 ET | Novartis Pharma AG
Arzerra significantly improved PFS when added to fludarabine + cyclophosphamide (median 28.9 mos vs 18.8 mos) after initial treatment stopped working  Patients receiving Arzerra plus existing...
NOVARTIS logo.jpg
Novartis reports new analysis showing Xolair® improving quality of life by 78% for chronic spontaneous urticaria patients
June 12, 2015 01:15 ET | Novartis Pharma AG
New analysis from pivotal Phase III studies show Xolair® (omalizumab) significantly improved quality of life scores for Chronic Spontaneous Urticaria (CSU) patients compared to placebo[1],[2]  ...
NOVARTIS logo.jpg
Novartis gains FDA approval for Promacta® providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder
June 11, 2015 17:08 ET | Novartis Pharma AG
Promacta® (eltrombopag) significantly increased and sustained platelet counts in two studies, including the largest Phase III clinical trial in this patient population Characterized by a low...
NOVARTIS logo.jpg
Novartis presents new data at WCD demonstrating significant efficacy of Cosentyx® in patients with psoriasis of the nails, palms and soles
June 11, 2015 16:30 ET | Novartis Pharma AG
Cosentyx (secukinumab) met the primary endpoints of superiority compared to placebo in patients with difficult-to-treat psoriasis of the nails, palms and soles[1],[2]  One third of patients with...
NOVARTIS logo.jpg
Novartis announces new one-year results demonstrating sustained secukinumab efficacy in ankylosing spondylitis patients
June 10, 2015 01:15 ET | Novartis Pharma AG
74% of patients in MEASURE 2 achieved clinically significant and sustained improvement in symptoms of ankylosing spondylitis (AS) with secukinumab 150 mg after one year of treatment[1]  AS is a...